Clinical Trial

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Name: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors — clinical trial record (NCT04803318)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2021-03-15; most recent amendment 2024-06-22.

Trial Details

NCT Number	NCT04803318
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University
Conditions	Solid Tumor, Adult, Hepatocellular Carcinoma
Enrollment	100 participants
Start Date	2021-01-01
Primary Completion	2029-01-01 (estimated)
Study Completion	2037-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-06-25